Credit Suisse resumed coverage on Fulgent Genetics with a new price target
$FLGT
Medical Specialities
Health Care
Credit Suisse resumed coverage of Fulgent Genetics with a rating of Underperform and set a new price target of $55.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2023 | $35.00 | Neutral | UBS |
| 12/8/2022 | $65.00 → $40.00 | Overweight → Neutral | Piper Sandler |
| 11/18/2022 | $45.00 | Outperform | Raymond James |
| 8/25/2022 | $65.00 | Outperform | Credit Suisse |
| 2/4/2022 | $80.00 | Overweight | Piper Sandler |
| 1/25/2022 | $141.00 → $125.00 | Outperform | Oppenheimer |
| 8/10/2021 | $55.00 → $65.00 | Underperform | Credit Suisse |
| 8/5/2021 | $55.00 | Underperform | Credit Suisse |
8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)
SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)